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Abstract PET using 18F-FDG for treatment monitoring in
patients with lymphoma is one of the most well-developed
clinical applications. PET/CT is nowadays used during treat-
ment to assess chemosensitivity, with response-adapted ther-
apy given according to ‘interim’ PET in clinical practice to
adults and children with Hodgkin lymphoma. PET is also used
to assess remission from disease and to predict prognosis in
the pretransplant setting. Mature data have been reported for
the common subtypes of aggressive B-cell lymphomas, with
more recent data also supporting the use of PET for response
assessment in T-cell lymphomas. The Deauville five-point
scale incorporating the Deauville criteria (DC) is recommend-
ed for response assessment in international guidelines. FDG
uptake is graded in relation to the reference regions of normal
mediastinum and liver. The DC have been validated in most
lymphoma subtypes. The DC permit the threshold for ade-
quate or inadequate response to be adapted according to the
clinical context or research question. It is important for PET
readers to understand how the DC have been applied in
response-adapted trials for correct interpretation and discus-
sion with the multidisciplinary team. Quantitative methods to
perform PET in standardized ways have also been developed
which may further improve response assessment including a
quantitative extension to the DC (qPET). This may have ad-
vantages in providing a continuous scale to refine the
threshold for adequate/inadequate response in specific clinical
situations or treatment optimization in trials. qPET is also less
observer-dependent and limits the problem of optical misin-
terpretation due to the influence of background activity.
Keywords Positron emission tomography . Lymphoma .
Diagnosis . Therapy . Precisionmedicine
FDG PET for monitoring therapy
and the development of the Deauville criteria
Monitoring of therapy in patients with lymphoma is one of the
earliest published indications for PET using 18F-FDG [1–3].
Studies in the 2000s showed high FDG uptake in aggressive
lymphomas, with rapid decreases in uptake occurring just two
or three cycles into a planned course of chemotherapy lasting
4–6 months [4–7]. A rapid decline in uptake was found to be
predictive of an excellent prognosis. Conversely, patients with
persistent uptake on these early ‘interim’ scans had inferior
prognosis, with progression-free survival (PFS) rates depen-
dent on the subtype and stage of disease. PFS rates around 85–
90% in larger series of patients with Hodgkin lymphoma (HL)
have since been reported [8–13] and 70–90% in patients with
aggressive non-Hodgkin lymphoma (NHL) [14–22] with a
good response on interim PET. PFS in patients with a poor
response on interim PET are inferior, at around 30–40% for
HL treated with doxorubicin, bleomycin, vinblastine,
dacarbazine (ABVD) chemotherapy [6, 13, 23], and 40–
60% in patients with diffuse large B-cell lymphoma
(DLBCL) [18, 20, 21]. Interim scans have become less dis-
criminating in aggressive NHL in recent years, probably ow-
ing to improved treatment outcomes in patients treated with
rituximab and better supportive care. This means that many
patients with an adverse appearance on an interim scan still
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achieve remission at the end of treatment. However, PET/CT
remains superior to CT assessment in this setting and is rec-
ommended for midtreatment imaging [24].
At the end of treatment, PET has proved to be highly pre-
dictive of disease remission, which is the goal of treatment.
Negative predictive values of 90–100% have been reported
for HL [11, 12, 25, 26] and aggressive NHL [14, 19, 27].
The positive predictive value is lower, because whilst FDG
accumulates in residual tumour, it may also be taken up in
inflammation induced by treatment. Published positive pre-
dictive values range from 50% to 100 [11, 12, 14, 19,
25–27] with variability again related to the initial disease
prognosis. To minimize inflammatory uptake, imaging should
be delayed for a minimum of 3 weeks, and preferably for 6–
8 weeks, after chemotherapy at the end of treatment, 2 weeks
after granulocyte colony-stimulating factor (GCSF) treatment
and 3 months after radiotherapy (RT) [24].
PETwas first included in response criteria alongside CT in
2007 as a way of confirming remission in patients with resid-
ual nodal masses [28, 29]. This led to the abolition of the
response category ‘complete response unconfirmed’ (CRu)
because PET is able to better differentiate patients with a
‘complete response’ (CR) from patients with a ‘partial re-
sponse’ (PR). A residual mass of any size that was considered
to be PET-negative was classified as CR, whilst a residual
mass that was considered to be PET-positive was classified
as PR or stable disease depending on the size on CT. This
approach improved the accuracy of remission assessment in
patients with high-grade NHL [30]. It was also accepted in the
2007 guidelines that PET-positive lesions could represent pro-
gressive disease, although the definitionwas still based on size
on CT. These 2007 International Harmonization Project (IHP)
criteria [28] restricted the use of PET to response assessment
at the conclusion of therapy in patients with HL and DLBCL
in clinical practice, with the use of interim imaging recom-
mended only in clinical trials.
However, the potential for PET to guide therapy in lympho-
ma, including interim scans, was well recognized by haemato-
oncologists [31]. The possibility to limit the amount of treatment
given to patients likely to be cured, to reduce toxicity was ap-
pealing. The opportunity to escalate therapy in the minority of
patients resistant to standard treatment was also an attractive
option. Clinical trials began around 2005 in patients with HL
followed by trials in patients with aggressive NHL to determine
if PET-guided therapy could improve outcomes.
The need for standardization of imaging protocols and PET
reporting in clinical practice and in trials was clearly recog-
nized. Indeed, the application of PET for response-adapted
treatment in lymphoma has been a key driver in the develop-
ment of the imaging technique as a whole. Standardization of
PET methods with the development of national research net-
works performing PET to commonly agreed quality assured
standards [32, 33] has since been extended from lymphoma to
other cancers. These methods are now generally recommend-
ed as best clinical practice [34–38].
Application and use of the Deauville criteria
Initial reports mostly referred to PET-negative and PET-
positive when reporting scans in lymphoma. Negative was
defined for example as ‘no evidence of disease’ and positive
as ‘any focal or diffuse area of increased activity in a location
incompatible with normal anatomy and suspicious for residual
disease’ on visual assessment [39]. The group at St. Thomas’
Hospital in London, however, acknowledged that varying
levels of FDG uptake could be seen in reports of their initial
experience, and in an attempt to grade residual uptake, intro-
duced the concept of ‘minimal residual uptake’ (MRU) [5, 6,
40]. MRU was termed as ‘low-grade uptake of FDG (just
above background) in a focus within an area of previously
noted disease reported by the nuclear medicine physician as
not likely to represent malignancy’ [40]. MRU is associated
with varying prognosis depending on the stage, lymphoma
subtype and timing of the scan during therapy [5, 6]. The
group further refined this by grading uptake using a five-
point scale initially referred to as the ‘South-East London
Cancer Network score’ for patients with lymphoma. The score
was used in the UK phase III trials sponsored by the National
Cancer Research Institute (NCRI) testing response-adapted
approaches in lymphoma and later by other research groups
[41]. The first international workshop on PET in lymphoma
was convened in Deauville to discuss solutions to deal with
the lack of uniform and reliable criteria for interim PET scan
interpretation [42]. It was concluded that this five-point scale
should be applied for reporting scans using visual analysis and
the additional value of standardized uptake value (SUV) anal-
ysis investigated. These criteria have since become widely
known as the Deauville criteria (DC) and are incorporated into
the Deauville five-point scale (Table 1, Fig. 1).
Recognizing that it would be years before clinical trials
testing PET response-adapted strategies would report, an in-
ternational group from the Deauville workshop and
Table 1 The Deauville five point scale. The scale scores the most
intense uptake in a site of initial disease, if present
Score Definition
1 No uptake
2 Uptake ≤ mediastinum
3 Uptake > mediastinum but ≤ liver
4 Moderately increased uptake compared to the liver
5 Markedly increased uptake compared to the liver
and/or new lesions
X New areas of uptake unlikely to be related to lymphoma
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subsequent workshops held in Menton, led by Professor
Meignan and Dr. Gallamini, set out to validate the DC and
to explore the ‘grey-zone’ area of MRU [42]. Cohorts of pa-
tient scans included in retrospective studies were collated and
reported by readers from Europe and the US using the DC [23,
43]. These validation studies demonstrated good interobserver
agreement and confirmed that the DC could predict outcome,
confirming earlier results using less stringent criteria [4–7].
Training sets developed for use in clinical trials and prospec-
tive testing of agreement between national imaging core lab-
oratories also showed good interobserver agreement in HL
[44] and aggressive NHL [45, 46]. These studies also sug-
gested refinements to the DC to further improve agreement.
In the 2007 IHP criteria, PET-positive scans were based
on ‘purely visual assessment with focal or diffuse uptake
above background in a location incompatible with normal
anatomy’ although ‘mild and diffusely increased uptake at
the site of masses ≥2 cm in diameter with intensity lower
than or equal to mediastinal blood pool structures’ was
regarded as PET-negative and likely due to post-therapy
inflammation [29]. Semiquantitative analysis was regarded
as unnecessary at that time.
The DC replaced IHP criteria in the updated international
guidance in 2014 because of the need for a scale that reflected
varying degrees of FDG uptake and the recognition that with
modern PET/CT cameras uptake much higher than back-
ground could still predict a good prognosis [24]. The use of
a graded scale also enables the threshold used to define a
‘negative’ or ‘positive’ scan to be adapted according to the
clinical context or research question. In most situations where
standard treatment will be given, a Deauville score (DS) of 3
represents a complete metabolic response (CMR). DS 3 has
also proved to be the most reproducible threshold amongst
reporters when interpreting PET scans in lymphoma patients.
Furthermore, using the DC improves the positive predictive
value of PET reporting compared to IHP and other criteria [15,
45, 47]. However, there is a caveat: if treatment is to be de-
escalated, to avoid the risk of under-treatment some investi-
gators have preferred to use the mediastinum (equivalent to
DS 2) to define CMR or a ‘negative’ scan [9, 10, 25, 48]. It is
important for reporters of PET to understand this and to report
using the DS for objective interpretation and appropriate clin-
ical management.
Refinements to the DC were included in the 2014 updated
international recommendations for response assessment [24].
These guidelines stated that areas of the body with high phys-
iological FDG uptake could have uptake higher than that of
normal liver, yet still be considered to represent CMR. This
applies to Waldeyer’s ring, bowel, spleen and bone marrow
activated by chemotherapy and/or GCSF. In such circum-
stances, uptake at a site of initial disease that does not exceed
that of surrounding normal tissue can be regarded as a CMR. It
was also suggested that where a persistent focal abnormality
was seen in the bone marrow in the context of a nodal re-
sponse, evaluation with MR, biopsy or an interval scan should
be considered as marrow changes may take longer to resolve
[49]. Guidance was also given regarding (semi)quantitative
assessment to assign DS 4 and 5 [24].
Fig. 1 Coronal slices of PET images in patients at staging and at response with different grades of FDG uptake, from left to right corresponding to
Deauville score 1–5
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Although initially developed for interim reporting, the DC
were also recommended for response assessment at the end of
treatment in the 2014 guidelines for staging and response as-
sessment of all FDG-avid lymphomas [24, 49]. Data strongly
indicate that PET/CT is more accurate than CT for remission
assessment in follicular lymphomas (FL) treated with
immunochemotherapy [50] as well as HL and aggressive
NHL. However, because FDG uptake is not specific for lym-
phomatous residual disease (Figs. 2 and 3), biopsy is recom-
mended if salvage treatment is considered, or at least an inter-
val scan, if the clinical index of suspicion is low.
In the relapsed/refractory setting prior to autologous stem
cell transplant, patients with a negative PET scan have better
outcomes than patients with persistent uptake following high-
dose chemotherapy in HL [51], DLBCL and FL [52]. Results
of more recent studies have been reported according to DC
with 3-year PFS in patients with DLBCL of 77% for DS 1–3
and 49% for DS 4 and 5 [53] and 3-year PFS in patients with
FL of 75% for DS 1–3 and 43% for DS 4 and 5 [52].
The largest amount of published data relates to the use of
PET in the common subtypes of HL, DLBCL and FL, which
together account for 70% of lymphomas. Recent data also
support the use of PET/CT for assessment of response in pe-
ripheral T-cell lymphomas [54–56] and extranodal NK/T-cell
lymphomas [57, 58]. In NK/T-cell lymphomas, the DC com-
bined with the presence/absence of Epstein-Barr virus (EBV)
is an accurate predictor of response to chemotherapy and che-
moradiotherapy [59]. Patients with a DS of 1 or 2 at the end of
Fig. 2 A 25-year-old woman
with Hodgkin lymphoma.
Maximum intensity projections of
FDG PET. a The initial staging
PET image reveals stage II dis-
ease. b The PET image after
six cycles of chemotherapy
(ABVD) shows PET-positive re-
sidual uptake at the left side of the
mediastinum (Deauville score 5).
c The PET image after involved
field radiotherapy now demon-
strates an additional focus of up-
take (physiological heart uptake is
suppressed on this scan). Biopsy
revealed posttreatment changes
only. d The interval PET image
12 months later shows resolution
of uptake
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treatment and EBV-negative status have a 15% relapse rate
after treatment compared to a 100% relapse rate in patients
with a DS of ≥3 with EBV-positive status or a DS of 5 irre-
spective of EBV status. In cutaneous T-cell lymphomas, de-
spite lower uptake in skin manifestations, PET has a role in
detecting suspected visceral involvement [60] that may occur
as the disease advances requiring systemic treatment, and in
guiding biopsy in patients with suspected transformation to
large cell disease [61].
The DC should now always be used to report response
assessment in FDG-avid lymphomas and can be used to as-
sign metabolic response categories (Table 2) [49]. Lymphoma
subtypes are mostly FDG-avid, although some do not consis-
tently take up FDG, including marginal zone lymphomas,
small lymphocytic lymphoma and some cutaneous lympho-
mas [62]. CT is reserved for lymphomas with low or variable
FDG avidity, or where PET is unavailable, and for evaluation
of new agents in multiply relapsed disease, where disease
control is more relevant than assessment of cure and data from
PET are minimal.
Emerging data suggest that patients with DS 5 have a sig-
nificantly worse prognosis than patients with DS 4 at the in-
terim assessment. In early stage HL, DS 5 is associated with a
higher risk of progression or death from HL than DS 1–4,
independent of pretreatment prognostic DS [63]. In advanced
stage HL, DS 5 is also associated with inferior PFS [64, 65]. In
primarymediastinal B-cell lymphoma, DS 4 is associatedwith
a good prognosis, probably due to inflammation in the large
residual mediastinal masses typical of this disease, but patients
with DS 5 have a high chance of relapse [66].
Quantification in response monitoring
Visual comparison of residual FDG uptake to uptake in the
reference regions of the mediastinum and liver is the currently
the defined standard for response interpretation in lymphoma
and its clinical suitability has been proven, especially in HL.
For clinical use, often a clear binary decision is desired—is the
PET response adequate or inadequate? This interpretation,
Fig. 3 A 15-year-old boy with
Hodgkin lymphoma. Maximum
intensity projections of FDG PET.
a The initial staging PET image
reveals stage III disease. b The
interim PET image after two cy-
cles of chemotherapy (OEPA)
shows PET-positive residual up-
take at the right side of the medi-
astinum (Deauville score 4). c
The PET image 4 months later
shows extensive relapse of the
disease (courtesy of Prof.
Reinhardt, Pius Hospital
Oldenburg)
Table 2 Using Deauville criteria to assign metabolic response categories
Category PET/CT-based metabolic response
Complete metabolic response Scores 1, 2 and 3a in nodal or extranodal sites with or without a residual mass using the five-point scale.
Partial metabolic response Score 4 or 5, with visually reduced uptake compared with baseline and residual mass(es) of any size.
At interim these findingsmay suggest responding disease; at end of treatment these findings indicate
residual metabolic disease.
Bone marrow: residual marrow uptake > normal marrow but reduced compared with baseline (diffuse
changes from chemotherapy allowed). If there are persistent focal changes in the marrow with a
nodal response, consideration should be given to MRI, biopsy or interval scan.
No metabolic response Score 4 or 5 with no significant change in uptake from baseline. At interim or end of treatment
Progressive metabolic disease Score 4 or 5 with an increase in uptake from baseline and/or new FDG-avid foci consistent with
lymphoma. At interim or end of treatment
Adapted from Cheson et al. [49]
a Score 3 probably represents CMR with standard treatment, but in trials where de-escalation is based on PET response, it may be preferable to consider
score 3 as inadequate response to avoid undertreatment.
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however, has to be made in the clinical context in relation to
lymphoma type, stage and risk factors such as bulk or B-
symptoms and the intensity of treatment given before and after
the PET scan. Whilst in many patients with classical HL,
hardly any residual uptake is present after two cycles of che-
motherapy, patients with DLBCL nearly always have residual
FDG uptake. Therefore, the degree of uptake considered ade-
quate for a patient with DLBCL might be considered inade-
quate for a patient with HL. Minor diffuse residual uptake in a
large bulky mass in a patient with stage IV HL also usually
represents an adequate response after two cycles, as planned
standard treatment with four to six more cycles will probably
induce remission. The same degree of residual uptake might,
however, be inadequate in a patient with stage II disease with-
out additional risk factors, who is already at the end of stan-
dard treatment.Modification in the interpretation of the degree
of FDG uptake may also be required for response-guided
treatment. A lower level of FDG uptake might be preferred
to define a so-called negative result in a clinical trial exploring
de-escalation to avoid undertreatment. A higher level of up-
takemight be preferred to define a so-called positive result in a
trial exploring escalation to avoid overtreatment [41].
Flexible criteria are, therefore, required. The change from
the binary IHP criteria to the ordinal five-point DS has offered
more flexibility to change the threshold between good and
poor response according to the clinical context and/or treat-
ment strategy. The intensity of residual uptake is, however, a
categorical number whereby the full information can only be
exploited using quantified methods. A continuous scale has
the potential for optimal thresholds to be derived for normal/
abnormal response for specific clinical situations or treatment
optimization in clinical trials. Quantitative assessment is less
user-dependent and circumvents optical misinterpretation due
to the influence of background activity. It can be fully auto-
mated and permit easier comparison between centres, facili-
tating multicentre trials [67].
Quantitative methods in oncology
Results from kinetic modelling or the Patlak-derived Ki cor-
relate well with the SUV in oncological studies [68]. Römer
et al. [69] showed good agreement between metabolic rate and
SUV for chemotherapy response in NHL. Due to its complex-
ity, full kinetic modelling is not typically undertaken for treat-
ment response monitoring with FDG [70] and the SUV is the
most widely used parameter for quantitative analysis. The
SUV is the ratio between the radiotracer concentration in a
voxel or group of voxels and the injected activity, divided by
a normalization factor, which is in clinical practice is usually
body weight. The SUV is readily available and well
established in routine clinical work. It is, however, affected
by a number of factors.
Differences in SUVs caused by differences in image acqui-
sition parameters (scanner, scatter and attenuation correction,
reconstruction algorithm) compromise the comparison of
SUVs acquired at different centres. This is of special relevance
in multicentre trials. Normalizing the tumour SUV to a refer-
ence region such as the liver in the same scan considerably
reduces this problem, since in general, the effect is present in
both regions and will at least partly, cancel each other out.
Therefore, tumour-to-reference organ SUV ratios rather than
direct SUV values should be used when comparing results
from different scanners.
Partial volume effects can cause a marked underestimation
of the true activity concentration within a tumour [71]. In
phantom experiments, for a spherical lesion with a diameter
1.5 times the spatial resolution of the PET scanner at full-
width at half-maximum, the measured maximum activity con-
centration is only about 60% of the true activity concentration
[72]. In patients, during or after chemotherapy, the most met-
abolically active tumour residual is often very small, especial-
ly in responding lymphomas. Therefore, the residual uptake
can be underestimated visually and quantitatively. The recon-
struction algorithm may considerably influence this. Use of
point spread function and time-of-flight reconstruction im-
proves the detectability and increases the SUVs of small le-
sions [73] while the SUVs of reference organs such as the liver
remain unaffected. In response evaluation, this effect may
compromise both the visual Deauville scoring and the quan-
titative tumour-to-reference organ SUV ratios [74, 75], For
response classification, it is therefore important to use stan-
dardized reconstruction methods as defined in the EANM
procedure guideline for tumour imaging, especially in
multicentre trials [36].
In most tumours, FDG uptake increases for at least 90 min
after injection [71]. Standardization of the uptake time is very
important, especially if the SUVof an individual patient will
be monitored serially during the disease course. In contrast to
tumour uptake, physiological FDG uptake in the liver or me-
diastinum does not increase over time. Thus, the tumour/
reference SUV ratio will increase over time, requiring the
use of a standardized time interval for determining tumour-
to-organ ratios or the DS.
SUVs and ratios are strongly influenced by the size of the
region. SUVmax is the uptake in the single voxel exhibiting the
highest tracer uptake. SUVmax is easily available, has good
interreader reproducibility and is relatively unaffected by par-
tial volume effects. SUVmax is, however, highly dependent on
the statistical quality of the images and is especially problem-
atic with small voxel sizes and low uptake. SUVmean is the
mean uptake in a larger user-defined region. A fundamental
biological question underlying the choice of region for
SUVmean is whether the total tumour volume or the most met-
abolically active portion is considered more important.
Concepts of stem cell biology suggest that the most aggressive
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portion is more important, meaning that regions with the
highest FDG uptake should be used for response assessment
[70]. Avariety of methods can be used to outline the volume of
interest (VOI) giving different sizes and different SUVmean
values. SUVpeak is the average of the SUVs in a group of voxels
surrounding the voxel with the highest activity. The idea is to
combine the good interreader reproducibility and low influence
of partial volume of the SUVmax with improved count rate
stability. In 2009, Wahl et al. proposed PERCIST for better
standardization of PET response criteria in solid tumours
[70]. A SUVpeak in a (relatively large) spherical VOI of 1 ml
is used, with semiautomatic positioning in the part of the tu-
mour with highest activity. The mean SUV in a fixed-size VOI
in the liver is used to measure reproducibility of serial data.
In the 2009workshop on PET in lymphoma, it was proposed
that SUV analysis should be explored [42] in addition to the
visual DS. Visual comparison is influenced by the size and
shape of the hottest residual uptake. It is not possible to look
selectively at the voxel with maximal uptake or at a predefined
peak area and to standardize the way different readers assess
this. The level of residual uptake may be influenced by the
adjacent background, giving misleading impressions of image
contrast [24, 76]. Thus, in cases with residual uptake similar to
the mediastinal or liver uptake, different observers may give
different DS [43, 77]. The group at St. Thomas’ Hospital,
London, recommends confirming visual evaluation by drawing
regions of interest around residual area(s) of uptake, if present,
and the normal mediastinum and liver. Regions of interest
should be drawn for the liver, avoiding the edge and any
individual/single ‘hot’ pixels likely to represent noise, sampling
several axial slices to obtain a representative maximum liver
SUV (Fig. 4) for comparison with the maximum SUV of the
tumour. Regions in the mediastinum should be drawn in the
arch of the aorta (or just above the aortic root in primary medi-
astinal B-cell lymphoma) [46] avoiding the vessel wall and any
areas of calcification (Fig. 4). Comparison of maximumSUVin
lesion and liver has also been proposed by other groups (‘rPET’
[78] and ‘Peking criteria’ [79]). Methods relying on SUVmax
can be usedwith current commercial workstations, but are high-
ly influenced by image noise.
Quantitative verification is of particular importance for dis-
crimination between DS 4 and DS 5. Now with mature data
published, DS 5 has been defined as three or more times the
maximum SUV in the liver by the UK NCRI group in their
trials and two or more times the maximum SUVin the liver by
the French and Belgian Lymphoma Studies Association and
Italian groups. Combining these, in the 2014 guidelines, it was
recommended that DS 5 be applied to uptake two to three
times the uptake in normal liver [24].
In 2014, the group of Leipzig, Germany, proposed the qPET
method as a quantitative extension of the DS [80]. In order to
increase the count rate stability of the measured values, the
SUVpeak of the residuum and the SUVmean of the liver are used
rather than SUVmax. This approach corresponds to PERCIST
recommendations for response assessment in solid tumours
[70]. The qPET value is the quotient of the SUVpeak of the
hottest residual over the SUVmean of the liver. The most meta-
bolically active part of HL residuals is typically very small.
Therefore, a VOI of 1 ml [70] for the calculation of SUVpeak
in solid tumours proved too large in HL. Hasenclever et al. [80]
defined the SUVpeak as the average value in the maximum SUV
voxel and the three hottest adjacent ones. The semiautomatic
seed-growing algorithm (Hermes Medical Solutions,
Stockholm, Sweden) is observer-independent. To characterize
the average liver uptake, a cuboid VOI of 30 ml (edge length
proportion 2:2:1) is positioned in the centre of the right lobe of
Fig. 4 Axial slices demonstrating
the St. Thomas’ method for
assessment of maximum SUV
within reference regions of the
liver (a) and mediastinum (b) for
confirmation of the Deauville
score (courtesy of Dr. Victoria
Warbey, PET Imaging Centre at
St. Thomas’ Hospital London)
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the liver. This VOI size allows easy positioning even in small
children but is large enough to give reproducible values for
SUVmean, regardless of precise positioning within the liver
(mean variation coefficient 3%). The authors independently de-
termined DS and qPET values in 898 paediatric HL patients
after two chemotherapy cycles and translated the ordinal
(visual) Deauville categories to thresholds on the continuous
qPET scale (Table 3). The method facilitates the use of the DC
but enables clear decisions and reduces interobserver differences
by standardizing regions and eliminating optical problems when
comparing grey levels (Fig. 5). Additionally, the continuous
scale offers a new approach to determining the best cutoff for
normal/abnormal response in individual clinical trials. The his-
togram of qPET values in paediatric HL demonstrated a
unimodal distribution with a pronounced peak suggesting ‘nor-
mal’ responses and a tail of outliers clearly indicating abnormal
responses. Mathematical mixture modelling can be used to cal-
culate the best cutoff. Based on this fitted model, patients with
qPET values below 1.3 (corresponding to DS 1–3) among the
898 patients had a probability of 97% of belonging to the normal
response group. The EuroNet clinical board decided to apply
qPET in the EuroNet-PHL-C2 trial in paediatric HL which
opened in 2015. The qPET method is semiautomatic, easy and
fast, but currently is available only on Hermes workstations.
Another approach to the quantification of PET response is
to determine ΔSUVmax, i.e. the difference between the
SUVmax of the lesions with the maximum uptake at baseline
and after one or more cycles of treatment, representing the
kinetics of tumour destruction [81]. This method has been
explored mostly in DLBCL. Compared to a visual three-
point score, Lin et al. showed an improved prognostic value
of ΔSUVmax after two cycles of chemotherapy in DLBCL
patients [82] with an optimal cutoff of −66%. Interestingly,
similar results were obtained using an SUVmax on interim PET
of 5.0, but this approachwas not pursued further. After four cy-
cles in the same patient group, a prognostic advantage of the
ΔSUVmax method over visual analysis was no longer seen,
even with the optimal cutoff of 70% [83]. Several trials have
confirmed the suitability of the ΔSUVmax method with a cut-
off of 66% after two cycles in DLBCL [43, 84]. After three or
four cycles, this criterion is less successful [22, 85, 86]. In one
trial involving DLBCL patients scanned after two or three cy-
cles, the best ΔSUVmax cutoff was determined as 76% [85],
and after three or four cycles, the bestΔSUVmax cutoff was as
high as 92% [86]. In this later stage of treatment, the prognos-
tic value of the ΔSUVmax method was not superior to the
visual DS (regarding DS4/5 as PET-positive).
Response-adapted treatment using FDG PET
In the last few years, clinical trials have begun reporting re-
sults using PET for response-adapted treatment. In HL, two
trials have been published exploring whether RT can be omit-
ted in patients with early-stage disease and a good response on
interim PET. The trials enrolled 1,589 and 602 patients, re-
spectively [9, 10]. The European H10 study had standard and
experimental arms,with a PETscan performed after two cycles
of ABVD (PET-2) in both arms. Patients in the standard arm
received three to six cycles of ABVD, the duration depending
on risk factors, followed by involved node RT (INRT).
Patients in the experimental arm with uptake the same as or
less than mediastinal uptake (equivalent to DS 2) on PET-2
continued with chemotherapy and were then randomized to
receive either INRT or no further treatment [10]. In the UK
RAPID study, with a similar design, patients were treated with
ABVD with a PET scan performed after three cycles [9].
Patients with uptake the same as or less than mediastinal up-
take (DS 2) stopped chemotherapy and were then randomized
to receive involved field RT (IFRT) or no further treatment.
Patients with uptake more than mediastinal uptake (DS3 or
greater) received a fourth cycle of ABVD and IFRT.
The ethos of investigators in these two studies was slightly
different. The H10 study was designed to test whether the
omission of RT would be noninferior to standard treatment
for early-stage HL, which is two to four cycles of ABVD che-
motherapy and 20–30 Gy RT. The RAPID investigators, how-
ever, considered that omitting RT was likely to result in some
worsening of disease control, which would be acceptable if
balanced by improvement in overall survival (OS), by reducing
the incidence of cardiopulmonary disease and second cancers,
and by not irradiating all patients. The randomized arm in the
H10 study for PET-negative patients was stopped early because
of futility, i.e. the results indicated that 1-year PFS for patients
who did not receive RTwas inferior to that in patients receiving
RT. The RAPID study continued to completion.
The results of the two studies are, however, similar. Both
trials demonstrated inferior PFS in patients who did not re-
ceive RT. In the RAPID study, patients with a PET-negative
scan who received RT had 3-year PFS of 97% and those who
did not receive RT had a 3-year PFS of 91% (HR 2.39,
p = 0.03 per protocol analysis). However, all patients with
PET-negative scans had a good prognosis in both trials with
Table 3 Translation of
semiautomatically
derived qPET values to
Deauville scores
qPET value Deauville score
0 1
<0.95 2
0.95 to <1.3 3
1.3 to <2.0 4
≥2.0 5
The qPET value is the quotient of themean
standard uptake value of the four hottest
connected voxels inside the tumour resid-
ual (SUVpeak) and the mean SUV of the
liver [80].
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1-year PFS in patients with a PET-negative scan of ≥94% in
the H10 study and a 3-year PFS of >90% in the RAPID study.
The RAPID investigators concluded that patients with a neg-
ative PETscan after three cycles of ABVD could avoid RT but
acknowledged that longer follow-up would be required to
determine if this wold result in improved OS by reducing
toxicity associated with RT. The decision as to whether an
individual patient today should receive RT needs to be care-
fully considered in consultation with a radiation oncologist
[87] and will probably depend on age, prognosis, fitness, dis-
ease distribution and the patient’s attitude to risk.
In advanced HL, the international UK-led RATHL trial
explored de-escalating treatment in patients with a CMR on
PET (defined as DS 1, 2 and 3) [8]. The study registered 1,214
patients. Patients were randomized after two cycles of ABVD
to continue to six cycles of treatment with the standard four
drugs or with bleomycin omitted, continuing with AVD for
three to six cycles. Bleomycin is associated with respiratory
side effects, especially in older patients. Patients did not re-
ceive RT in this trial, which is often given to sites of initial
bulk as part of standard treatment. Three-year PFS was not
significantly different between patients receiving ABVD and
those receiving AVD (HR 1.13, p = 0.35), but patients receiv-
ing AVD had less infection, neutropenic fever and respiratory
adverse events. The investigators concluded that patients with
an early CMR can safely have bleomycin omitted from treat-
ment in cycles three to six with reduced toxicity.
Patients with advanced HL are commonly treated with
six cycles of ABVD in some parts of Europe and the USA.
However, in other parts of Europe, six to eight cycles of
bleomycin, etoposide, doxorubicin, cyclophosphamide, vin-
cristine, procarbazine, prednisolone (BEACOPP) is preferred
for first-line treatment. ABVD cures around 70–80% of pa-
tients, whereas BEACOPP cures 5–10% more patients but
with a worse side effect profile including more acute haema-
tological toxicity and increased risk of infertility and second
malignancies [88]. Chemotherapy is usually followed by RT
to sites of initial bulk.
The H10 and the RATHL studies attempted to evaluate
whether BEACOPP chemotherapy could be reserved for
patients with an early PET-positive scan, thereby reducing
side effects overall.
In the H10 trial patients with early-stage disease and a PET-
positive scan (DS 3, 4 and 5) were randomized to receive
ABVD or BEACOPP then INRT [10]. In the RATHL trial
all patients with advanced disease and a PET-positive scan
(DS 4 and 5) were treated with BEACOPP chemotherapy
but no RT [8]. The H10 study demonstrated significantly bet-
ter PFS in PET-positive patients receiving BEACOPP and
INRT than in patients receiving ABVD and INRT, with 5-
Fig. 5 Initial (a) and interim FDG PET/CT (b, c) images in a patient with
Hodgkin lymphoma. b Residual FDG uptake after two cycles of chemo-
therapy lies in the residual mass at the right side of the mediastinum. The
intensity of the residual uptake is similar to the liver uptake; two inde-
pendent readers scored this as Deauville scores 3 and 4, respectively. c
Semiautomatic determination of the qPET value. Cyan box 30-ml VOI in
the liver with SUVmean 1.59; small red box four-voxel VOI in hottest part
of the residuum with SUVpeak 2.34: qPET = 2.34/1.59 = 1.47, corre-
sponding to Deauville score 4 (see Table 3)
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year PFS of 91% and 77%, respectively. RATHL demonstrat-
ed 3-year PFS of 67% for PET-positive patients treated with
BEACOPP compared with historical reports of PFS at 2–
3 years of 20–30% in PET-positive patients with advanced
disease treated with ABVD [7, 23]. Both trials suggested that
patients with a PET-positive scan have better outcomes if es-
calated from ABVD to BEACOPP, sparing >80% of patients
the side effects associated with BEACOPP.
The Italian HD0801 also used a PET response-adapted ap-
proach in patients with advanced disease after two cycles of
ABVD [89]. Patients with PET-negative scans (n = 409) con-
tinued with ABVD, whereas patients with a PET-positive scan
(n = 101) were treated with high-dose chemotherapy and bone
marrow transplantation. Patients with a PET-positive scan had
similar PFS to patients with a PET-negative scan with 2-year
PFS of 74% and 81%, respectively, again suggesting that out-
come can be improved with treatment escalation if early PET
demonstrates chemoresistance to ABVD.
The German HD15 study used PET to decide whether pa-
tients with a residual mass ≥2.5 cm at the end of BEACOPP
treatment should receive RT [25]. The more conservative medi-
astinal threshold (DS 2) was used to define response. PET was
performed in 881 patients, 74% of whom had a negative PET
scan and did not receive RT. Patients with a complete radiolog-
ical response had the same PFS as patients with a PET-negative
PR, suggesting that patients with a CMR do not require RT
following BEACOPP. PET-positive patients who received RT
had an inferior prognosis with 2-year PFS of 86% in contrast to
93% in PET-negative patients, suggesting that resistance to che-
motherapy is not completely overcome with RT.
These approaches are beginning to be used in clinical prac-
tice. However, the 3-year PFS rate in the RATHL trial of 85%
for patients with advanced disease was lower than anticipated
for patients with interim PET-negative scans, and there is
room for improvement in treatment outcomes for patients with
advanced disease and interim PET-positive scans.
The role of newer agents including the anti-CD30 anti-
body–drug conjugate brentuximab vedotin which showed
good efficacy in relapsed and refractory disease [90] is cur-
rently being explored in the first-line setting in the
‘ECHELON’ trial combined with AVD (https://clinicaltrials.
gov/ct2/show/NCT01712490).
In the RATHL trial, the DS in PET-negative patients (DS 1 vs.
DS 2 vs. DS 3) did not influence PFS, suggesting that DS 3 is
likely to represent CMR with standard treatment. However, it
may be prudent to use DS 2 when omission of RT is being
considered [49]. It is important therefore to report using the DC
and to be aware of the implications of the different scores when
patients will be treated using a PET response-adapted approach.
In paediatric HL, the first trial systematically using FDG
PET to tailor treatment intensity was the EuroNet-PHL-C1
trial. This trial recruited 2,111 patients with classical HL (all
stages) from 18 European countries between 2007 and 2013
[91] (http://clinicaltrials.gov/ct/show/NCT00433459:2012).
A Paediatric Hodgkin Network was created to transfer
images for central review [92]. Interim PET was performed
after two cycles of vincristine, etoposide, prednisone and
doxorubicin (OEPA). RT was completely eliminated in
patients with an adequate PET response using IHP criteria.
The hypothesis was that event-free survival (EFS) would be
similar to that of the preceding GPOH-HD-2002 trial using
identical chemotherapy in spite of reduced use of RT. RTwas
omitted in about 50% of patients [77]. The results of the trial
are not mature, but publication is anticipated by the end of
2017. In 2015, the EuroNet-PHL-C2 trial started recruitment
of paediatric HL patients with 22 countries expected to partic-
ipate. As in the C1 trial, all patients have interim PET for early
response assessment after two cycles of OEPA. In contrast to
the C1 trial, for definition of response, the qPET-method is
used. A qPET value of ≤1.3 corresponding to a DS of ≤3 is
considered an adequate response. It is expected that about
75% of patients will have a DS of ≤3 and will not receive RT.
The COG AHOD0831 trial was the first trial from the
Children’s Oncology Group using PET to adapt treatment in
HL. It included only patients with very high-risk disease. The
IHP criteria were used after one and two cycles. PET-negative
patients after two cycles of doxorubicin, bleomycin, vincristine,
etoposide, cyclophosphamide and prednisone (ABVE-PC) re-
ceived standard chemotherapy while slow responders received
therapy augmentation with two cycles of ifosfamide/
vinorelbine followed by RT to sites of initial bulk. Four-year
EFS was 91.9% in PET-negative patients and 87.8% in PET-
positive patients after augmented treatment [93].
A response-adapted design has failed to improve patient
outcomes in several recent prospective trials in patients with
aggressive NHL [94] with the exception of one study presented
by the Australian Leukemia and Lymphoma Group [95]. This
study enrolled 162 patients with poor prognosis DLBCL.
Patients with a PET-positive scan after four cycles of rituximab
and cyclophosphamide, doxorubicin, vincristine and predni-
sone (R-CHOP) were treated with Zevalin and high-dose che-
motherapy. Patients with a PET-negative scan continued to
six cycles of R-CHOP with two additional rituximab cycles.
PFS in PET-positive patients (DS 4 and 5) and PET-negative
patients was not statistically significantly different: 2-year PFS
was 67% and 74%, respectively (p = 0.32), and 2-year OS was
78% and 88%, respectively (p = 0.11). In other trials, however,
whilst the interim PET result was predictive of patient out-
comes in the larger studies presented [96–98], outcomes were
not improved using alternative treatment approaches. Unlike
HL, in NHL, there are limited options other than the standard
treatments of R-CHOP or R-doxorubicin, cyclophosphamide,
vindesine, bleomycin and prednisone (R-ACVBP), a more in-
tensive regimen used in younger patients, although trials are
now investigating combinations of R-CHOP with immuno-
modulatory agents such as lenalidomide and idelalisib [99].
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Role in RT planning
PET is becoming increasingly important in planning RT in
patients with lymphoma. Treatment of smaller volumes has
become possible through better staging of disease with PET
and the ability to deliver RT more precisely using modern
techniques such as intensity modulated RT (IMRT). A recent
review showed that PET modifies the treatment volume in up
to 70% of cases [100]. International guidelines now recom-
mend that PETshould be used when INRTor involved site RT
(ISRT) is employed rather than older IFRT [101, 102].
Summary
PET is an integral part of monitoring therapy in lymphomas.
PET is used to assess remission from disease but more recent-
ly has become an important tool to guide response-adapted
treatment in adults and children with HL, enabling de-
escalation in some patients with reduced toxicity and escala-
tion in others to improve outcomes. PET/CT is used to deter-
mine the need for RT and to plan treatment volumes using
IMRT enabling a move away from the use of IFRT to ISRT
and INRT. The DC have evolved as a standardized method for
monitoring disease response, with quantitative approaches in
development to further improve the quality and reproducibil-
ity of PET response assessment.
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